Introduction
Glycopeptide antibiotics such as vancomycin and teicoplanin are often used for the treatment of severe life-threatening infections when no other agents are effective or available. Unfortunately, high level bacterial resistance has significantly eroded the effectiveness of these 'drugs of last resort' over the past decade [l] . There is an urgent need for new antimicrobial agents in this class to overcome emerging resistance, and this need is propelling new investigations into the mode and site of action of glycopeptide antibiotics.
An important insight into the process by which glycopeptide antibiotics recognize their target ligands in bacterial cell walls was provided through nuclear magnetic resonance (NMR) investigations that suggested that these antibiotics formed dimers [Z-.5] and that dimerization could significantly enhance ligand affinity [6-141. It was concluded that vancomycin dimerized in a 'back-to-back' configuration, with segments of antiparallel p structure forming both at the 'back' of each monomer, across the dimer interface between heptapeptide backbones, and at the 'front' of each monomer, between the drug and its ligand. X-ray crystallography has since verified this back-to-back antiparallel p configuration in balhimycin and vancomycin crystals, and has also shown that the aromatic rings and the sugar residues in these compounds engage in an extensive array of interactions across the dimer interface [S-17] .
Dimerization is believed to promote antimicrobial action because the binding of one monomer to the bacterial cell wall brings a second monomer into proximity with other peptidoglycan ligands, leading to the formation of a 'chelate' with the peptidoglycan [8, 14] . Back-to-back dimerization also increases the affinity between ligands and individual monomers, however [6, 12, 14] . At least three mechanisms have been suggested to explain this allosteric effect. First, dimerization may induce conformational changes, or suppress thermomolecular deformations, and thereby yield a more favorable site for ligand binding 112,171. Second, dimerization may position positively charged groups such that the negatively charged carboxyl terminus of a ligand is attracted into the binding site [12] . Third, antiparallel p structure in a dimer may polarize the backbone peptide groups involved in ligand binding and strengthen their hydrogen-bonding potential [17] . These mechanisms are mutually compatible, and all may contribute to ligand affinity.
Recent investigations demonstrate that covalently linked vancomycin monomers can show markedly increased affinity for depsipeptide ligands and significant antimicrobial activity against vancomycin-resistant bacteria [l&19]. These properties, and the requirement for rather long molecular linkages between vancomycin monomers (> 10 if), suggest that covalent linkage does not enhance activity by promoting the same types of interactions found in noncovalent back-to-back dimers. In this report, we describe the crystal structure of vancomycin in complex with N-acetyl-D-alanine (AcDA). This complex illustrates the ability of vancomycin to form 'face-to-face' dimers, and suggests that face-to-face interactions may account for the enhanced ligand affinity and antimicrobial efficacy of covalently linked monomers.
Results and discussion

Nomenclature
Residues in the vancomycin-AcDA structure are referred to in a similar manner to those described previously by Loll et al. [17] . The four independent molecules of vancomycin are designated VI-V4, with the seven individual amino acid residues within each monomer designated Vl:l-V1:7, VZ:l-V2:7, and so on (Figure 1 ). The glucose and vancosamine residues are indicated by 'G' or 'V' in place of a residue number. The corresponding ligands are designated AcDAl-AcDA4, and there are four chloride ions, Cl-l-Cl-4 in each asymmetric unit.
Structure description
There are four copies each of vancomycin, AcDA and Clin the asymmetric unit of vancomycin-AcDA crystals, implying that four countercations remain unidentified. These molecules form two asymmetric dimers (Vl-V3 and VZ-V4), similar to those seen in the ureido-balhimycin and vancomycin-acetate structures (Figure 2 ). VI and V2, along with their ligands, are nearly identical and may be superimposed with a root mean square (rms) difference of < 0.2 A. The configuration of their disaccharides corresponds to that seen in the ligand-bound monomer of the vancomycin-acetate complex (VZ), that is the glucose residue overhangs the ligand-binding site. Likewise, V3 and V4 are nearly identical and Fay be superimposed with an rms difference of < 0.2 A. The configuration of their disaccharides, however, corresponds to that of the ligand-free monomer of the vancomycin-acetate complex (VI), so the vancosamine residue overhangs the ligand-binding site. Apart from opposite orientations for the disaccharides, Vl and VZ are quite similar to V3 and V4, and may be superimposed with an rms difference of < 0.4 A.
The charged amino groups of Vl:V and V2:V hydrogen bond with the backbone carbonyl oxygen atoms of V2:2 and V1:2, respectively. These relationships are analogous to those found across the dimer interface in the crystal structure of vancomycin between the charged amino group of vancosamine on residue 6 and the backbone carbony1 of residue 2. It is noteworthy that the carbonyl groups of V3:2 and V4:2 are not similarly bound, but that electron densities assigned to water molecules 8 and 20 may be sodium cations in analogous positions.
Ligand binding
The ligand in Vl and V2 of the AcDA complex is situated slightly higher in the binding site than in V3 and V4 (when oriented with the disaccharide upwards). The chief interaction causing this difference appears to be steric repulsion between the C, methyl of vancosamine in V3/V4 and the alanyl methyl group of the ligand. The ligands adopt essentially the same configuration in all four binding sites, however, with backbone 9 angles in the range of -22.7 to -26.2" [ZO] .
The vancomycin-AcDA complex adopts a different crystal form than either the acetate or N-acetyl-glycine complexes ([17] ; P.J.L., unpublished observations), which reflects the differences in affinity between the drug and these different ligands. The ratio of vancomycin:ligand is 1:l in the AcDA complex, whereas it is 21 in the acetate and glycine complexes. Molecule Vl in the acetate and glycine complexes is bound to a symmetry-related copy of itself (residue Vl:l) instead of to the ligand. Thus, AcDA presumably has a higher affinity for the binding site than Vl:l, thereby precluding formation of the crystal form seen in acetate and glycine crystals.
Dimer formation
Vancomycin-AcDA forms back-to-back dimers as seen previously in the crystal structures of balhimycin [15] and vancomycin-acetate [16, 17] . Of interest, however, is the observation that Vl, in addition to forming the back-toback dimer with V3, also forms a face-to-face dimer with a symmetry-related copy of V3 (Figure 3) . The same relationships are observed between V2 and V4. The bound AcDA ligands comprise a significant portion of these faceto-face dimer interfaces. Direct contact between Vl and V3 is limited to hydrophobic interactions between Vl:l and V3:l (similarly for V2:l and V4:1), but the ligand bound to Vl makes more extensive contact with V3, Crystals were grown by hanging drop vapor diffusion. Equal volumes of aqueous vancomycin hydrochloride (40 mg ml-') and reservoir buffer were mixed and equilibrated over reservoir buffer at 20°C; the reservoir buffer was 2.1 M NaCl in 0.1 M /V-acetyl-o-alanine, pH 4.6. Prior to data collection, crystals were transferred to a solution of 30% (v/v) glycerol in reservoir buffer, mounted in fiber loops, and flashcooled by plunging into liquid N,. Crystals were maintained at -175% in a stream of N, gas during data collection.
Data collection
High-resolution data were collected at beamline Xl 2-B at NSLS, using a MAR 30 cm image plate detector.
Because of overloading in the intense low resolution data, further data were taken from the same AcDA crystal using a MAR 30 cm detector mounted on a home source. These data were merged with the high resolution synchrotron data and used during refinement.
Data were processed with DENZO and SCALEPACK; details are given in 
